FAQ

The first TEX Core oncology compound to be developed is OxaliTEX, a conjugation of oxaliplatin and texaphyrin, which localizes to solid tumors including ovarian, lung and colorectal cancers.

Preclinical research has shown OxaliTEX is more effective than traditional platinum-based chemotherapy, with the ability to overcome multifactorial resistance, including reactivation of the mutated p53 tumor suppressor gene, a primary reason current therapies fail. OxaliTEX is also visible on MRI, meaning physicians can identify tumor locations and monitor response to treatment.

World first TEX Core platform facilitates the chemical conjugation of oncology therapies with texaphyrin, creating novel oncology compounds that are delivered directly to tumor cells with minimal side effects.

86% of patients experience side effects from traditional chemotherapy treatments and 27% of those side effects are potentially life threatening³.

TEX Core developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies.

The lead indication for OxaliTEX is ovarian cancer, the number one cause of gynecological cancer deaths globally. With the ability to kill cancer cells, even in platinum resistant tumors, OxaliTEX provides new hope for ovarian cancer patients.

Following ovarian cancer, the future applications include lung cancer, colorectal cancer and Glioblastoma multiforme (GBM) a type of brain tumor.

As OxaliTEX addresses an unmet clinical need in platinum-resistant ovarian cancer, OncoTEX Inc. plans to utilise a regulatory approval pathway which expedites treatments with orphan drug status. The unmet need:

Every year, almost 300,000 women are diagnosed with ovarian cancer globally¹⁸.

The incidence of ovarian cancer is expected to increase 55% by the year 2035¹⁷.

Resistance is a key issue in ovarian cancer with 70-80% of patients becoming resistant, which leads to disease progression¹².

The iQ Group Global acquired the anticancer drug platform, TEX Core, in 2019. The first TEX Core oncology compound to be developed is OxaliTEX, a conjugation of oxaliplatin and texaphryn, which localizes to solid tumors including ovarian, lung and colorectal cancers. OncoTEX, a member company of The iQ Group Global, continues its development in partnership with the University of Texas and the MD Anderson Cancer Center.

Preliminary research evidence has been reported in the international medical journal Proceedings of the National Academy of Sciences.  

OncoTEX Inc. has licensed the IP (consisting of more than 20 patents and patent applications) to the novel anticancer drug platform, TEX Core, that develops well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug-resistant solid tumours from the University of Texas at Austin.

Current platinum-based anticancer drugs have limitations.  Almost half of all chemotherapy patients are treated with platinum-based drugs such as cisplatin, carboplatin and oxaliplatin. While these drugs kill cancer cells, they are also toxic to healthy cells, resulting in debilitating side effects. Over time, traditional chemotherapy drugs can become ineffective as cancer cells develop drug resistance to platinum-based chemotherapies. 

OxaliTEX is currently in the preclinical stage. Early demonstration batches and clinical-grade OxaliTEX are currently being manufactured. Following this, we will evaluate the safety of OxaliTEX per regulatory standards.